WO2002058731A3 - Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions - Google Patents

Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions Download PDF

Info

Publication number
WO2002058731A3
WO2002058731A3 PCT/US2002/001196 US0201196W WO02058731A3 WO 2002058731 A3 WO2002058731 A3 WO 2002058731A3 US 0201196 W US0201196 W US 0201196W WO 02058731 A3 WO02058731 A3 WO 02058731A3
Authority
WO
WIPO (PCT)
Prior art keywords
absorption inhibitor
sterol absorption
combinations
treatment
cardiovascular agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/001196
Other languages
French (fr)
Other versions
WO2002058731A2 (en
Inventor
Teddy Kosoglou
Rudyard Joseph Ress
John Strony
Enrico P Veltri
William Hauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27500817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002058731(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR10-2003-7009793A priority Critical patent/KR20040025889A/en
Priority to CA002434436A priority patent/CA2434436A1/en
Priority to DE60220269T priority patent/DE60220269T2/en
Priority to MXPA03006724A priority patent/MXPA03006724A/en
Priority to BR0206644-0A priority patent/BR0206644A/en
Priority to IL15658502A priority patent/IL156585A0/en
Priority to EP02707500A priority patent/EP1385548B1/en
Priority to AU2002241903A priority patent/AU2002241903B2/en
Application filed by Schering Corp filed Critical Schering Corp
Priority to HK04103917.0A priority patent/HK1060854B/en
Priority to DK02707500T priority patent/DK1385548T3/en
Priority to SK949-2003A priority patent/SK9492003A3/en
Priority to HU0303923A priority patent/HUP0303923A2/en
Priority to JP2002559065A priority patent/JP2004517919A/en
Priority to RU2003126186/15A priority patent/RU2003126186A/en
Priority to SI200230555T priority patent/SI1385548T1/en
Publication of WO2002058731A2 publication Critical patent/WO2002058731A2/en
Priority to NO20033358A priority patent/NO20033358L/en
Anticipated expiration legal-status Critical
Publication of WO2002058731A3 publication Critical patent/WO2002058731A3/en
Priority to CY20071101045T priority patent/CY1106791T1/en
Priority to IL190173A priority patent/IL190173A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols.
PCT/US2002/001196 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions Ceased WO2002058731A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SI200230555T SI1385548T1 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
DK02707500T DK1385548T3 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor (s) with cardiovascular (s) for the treatment of vascular conditions
DE60220269T DE60220269T2 (en) 2001-01-26 2002-01-25 COMBINATIONS OF A STEROLABSORPTION HEMMER AND A CARDIOVASCULAR ACTIVE AGENT FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS
MXPA03006724A MXPA03006724A (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions.
BR0206644-0A BR0206644A (en) 2001-01-26 2002-01-25 Sterol absorption inhibitor (s) combinations with cardiovascular agent (s) for the treatment of vascular conditions
IL15658502A IL156585A0 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
EP02707500A EP1385548B1 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
HU0303923A HUP0303923A2 (en) 2001-01-26 2002-01-25 Combinations of sterol absorbtion inhibitor(s) with cardiovascular agents for treatment cardiovascular conditions and pharmaceutical compositions containing the combination
CA002434436A CA2434436A1 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
HK04103917.0A HK1060854B (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
SK949-2003A SK9492003A3 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
KR10-2003-7009793A KR20040025889A (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
AU2002241903A AU2002241903B2 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
JP2002559065A JP2004517919A (en) 2001-01-26 2002-01-25 Combination of cardiovascular drugs and sterol absorption inhibitors for treatment of vascular conditions
RU2003126186/15A RU2003126186A (en) 2001-01-26 2002-01-25 COMBINATIONS OF INHIBITOR (INHIBITORS) OF SUCTION OF STERIN WITH A CARDIOVASCULAR AGENT (AGENTS), INTENDED FOR TREATMENT OF PATHOLOGICAL CONDITIONS OF VESSELS
NO20033358A NO20033358L (en) 2001-01-26 2003-07-25 Combinations of sterol absorption inhibitor and cardiovascular agents for the treatment of vascular disorders
CY20071101045T CY1106791T1 (en) 2001-01-26 2007-08-07 COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIAC AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS
IL190173A IL190173A0 (en) 2001-01-26 2008-03-13 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26439601P 2001-01-26 2001-01-26
US26427501P 2001-01-26 2001-01-26
US26460001P 2001-01-26 2001-01-26
US60/264,600 2001-01-26
US60/264,275 2001-01-26
US60/264,396 2001-01-26
US32384201P 2001-09-21 2001-09-21
US60/323,842 2001-09-21

Publications (2)

Publication Number Publication Date
WO2002058731A2 WO2002058731A2 (en) 2002-08-01
WO2002058731A3 true WO2002058731A3 (en) 2003-11-20

Family

ID=27500817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001196 Ceased WO2002058731A2 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions

Country Status (27)

Country Link
US (1) US20030069221A1 (en)
EP (3) EP2039357A2 (en)
JP (1) JP2004517919A (en)
KR (2) KR20040025889A (en)
CN (1) CN1582168A (en)
AR (2) AR032643A1 (en)
AT (1) ATE362757T1 (en)
AU (1) AU2002241903B2 (en)
BR (1) BR0206644A (en)
CA (1) CA2434436A1 (en)
CY (1) CY1106791T1 (en)
CZ (1) CZ20032031A3 (en)
DE (1) DE60220269T2 (en)
DK (1) DK1385548T3 (en)
EC (1) ECSP074704A (en)
ES (1) ES2286233T3 (en)
HU (1) HUP0303923A2 (en)
IL (2) IL156585A0 (en)
MX (1) MXPA03006724A (en)
NO (1) NO20033358L (en)
NZ (1) NZ545332A (en)
PL (1) PL369033A1 (en)
PT (1) PT1385548E (en)
RU (1) RU2003126186A (en)
SI (1) SI1385548T1 (en)
SK (1) SK9492003A3 (en)
WO (1) WO2002058731A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
HUP0401501A3 (en) * 2001-09-21 2012-02-28 Schering Corp Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
MXPA04011530A (en) 2002-05-21 2005-08-15 Cv Therapeutics Inc Method of treating diabetes.
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7358390B2 (en) * 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US20050075400A1 (en) * 2002-07-18 2005-04-07 Ronit Yahalomi Polymorphic forms of nateglinide
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) * 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
AR040588A1 (en) 2002-07-26 2005-04-13 Schering Corp PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE
WO2004028470A2 (en) * 2002-09-27 2004-04-08 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
ES2636943T3 (en) 2003-05-09 2017-10-10 Toray Industries, Inc. Beraprost and a renin-angiotensin system inhibitor for use in the treatment of kidney diseases
JP2005015434A (en) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk Serum cholesterol lowering agent or preventive or therapeutic agent for atherosclerosis
JP2007502831A (en) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
AU2008201290B2 (en) * 2003-09-26 2010-12-09 Astrazeneca Uk Limited Therapeutic treatment
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
US7932268B2 (en) 2004-03-05 2011-04-26 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
ES2282062T1 (en) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN.
WO2006083779A2 (en) * 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
RU2441653C2 (en) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Compositions containing nebivolol
AP2896A (en) * 2005-05-31 2014-05-31 Mylan Lab Inc Compositions comprising nebivolol
SA06270191B1 (en) 2005-06-22 2010-03-29 استرازينيكا ايه بي Novel 2-Azetidinone Derivatives as Cholesterol Absorption Inhibitors for the Treatment of Hyperlipidaemic Conditions
EA200800451A1 (en) * 2005-07-28 2008-08-29 Релайэнт Фармасьютикалз, Инк. TREATMENT OF DIHYDROPYRIDINE BLOCKERS OF CALCIUM CHANNELS AND FATTY ACIDS OF OMEGA-3 AND THEIR COMBINED PRODUCT
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
JP5179354B2 (en) * 2005-09-15 2013-04-10 大塚製薬株式会社 Concomitant drugs containing probucol and tetrazolylalkoxy-dihydrocarbostyril derivatives having superoxide inhibitory effect
EP1951220A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Compositions for lowering serum cholesterol and/or triglycerides
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
US20080139527A1 (en) * 2006-12-08 2008-06-12 Reddy Kota J Methods for treatment of heart disease
WO2008076841A1 (en) * 2006-12-14 2008-06-26 Biokey, Inc. Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases
CA2673290A1 (en) * 2006-12-21 2008-07-03 Aegerion Pharmaceuticals, Inc. Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor
EP2117550A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2042179A1 (en) * 2007-09-26 2009-04-01 sanofi-aventis Novel therapeutic uses of adrenergic alpha-1 receptor antagonists
KR20090091085A (en) * 2008-02-22 2009-08-26 한올제약주식회사 Pharmaceutical Release Controlled Release
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2414529A2 (en) 2009-04-01 2012-02-08 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
RU2570752C2 (en) * 2011-08-26 2015-12-10 Вокхардт Лимитед Method of treating cardiovascular diseases
EP2727587A1 (en) * 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (en) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
KR20150120008A (en) * 2014-04-16 2015-10-27 씨제이헬스케어 주식회사 Pharmaceutical combinations for oral use containing bisoprolol and rosuvastatin
WO2016155815A1 (en) * 2015-04-01 2016-10-06 Ceva Sante Animale Oral solid dosage form of amlodipine and veterinary uses thereof
US20230285376A1 (en) 2020-07-29 2023-09-14 Amryt Pharmaceuticals Inc. Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
KR102816341B1 (en) * 2022-01-24 2025-06-05 연세대학교 산학협력단 Composition for prevention or treatment of cardiovascular disease
CN120093759B (en) * 2025-02-24 2026-04-14 华中科技大学同济医学院附属同济医院 Pharmaceutical composition for preventing or treating arteriosclerosis and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
US3108097A (en) * 1963-10-22 Ehnojs
US1286A (en) * 1839-08-13 Richard else
BE578515A (en) * 1958-05-07
NL127065C (en) * 1964-04-22
NL137318C (en) * 1964-06-09
FI52570C (en) * 1969-04-16 1977-10-10 Sumitomo Chemical Co Process for producing the cholesterol or lipoid content of the blood using phenoxyaliphatic carboxylic acid compounds and ester compounds.
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (en) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarboxylic acid derivatives and processes for making the same
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (en) * 1977-09-19 1979-04-13 Lafon Labor NEW PROCESS FOR THE PREPARATION OF PHARMACEUTICAL, COSMETIC OR DIAGNOSIS FORMS
IT1157365B (en) * 1977-10-24 1987-02-11 Sandoz Ag MEDICATIONS TO TREAT OBESITY OR REDUCE BODY WEIGHT
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3107100A1 (en) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen AZAPROSTACYCLINE, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
US4614614A (en) * 1983-03-28 1986-09-30 Ciba-Geigy Corporation Process for the manufacture of optically active azetidinones
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
WO1985004876A1 (en) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (en) * 1984-03-30 1987-12-11 Lafon Labor GALENIC FORM FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT BY LYOPHILIZATION OF AN OIL-TO-WATER EMISSION
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (en) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
EP0234484B1 (en) * 1986-02-19 1993-10-20 Sanraku Incorporated Novel azetidinone derivatives
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2598146B1 (en) * 1986-04-30 1989-01-20 Rech Ind NEW PROCESS FOR THE PREPARATION OF FIBRATES.
DE3621861A1 (en) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg USE OF ARYLOXYCARBONIC ACID DERIVATIVES AGAINST DERMATOLOGICAL DISEASES
FR2602423B1 (en) * 1986-08-08 1989-05-05 Ethypharm Sa PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
JPS63156788A (en) * 1986-12-22 1988-06-29 Sanraku Inc Optically active azetidinones
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
EP0288973B1 (en) * 1987-04-28 1993-01-13 Fujisawa Astra Ltd. Benzothiazolinone derivatives, their production and pharmaceutical composition
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
FR2627696B1 (en) * 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
DE3807895A1 (en) * 1988-03-10 1989-09-21 Knoll Ag PRODUCTS CONTAINING A CALCIUM ANTAGONIST AND A LIPID DOWNER
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (en) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-ARYL-AZETIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ELASTASE INHIBITORS
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
JPH03108490A (en) * 1989-06-30 1991-05-08 Shionogi & Co Ltd Phospholipase a2 inhibitor
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP2640986B2 (en) * 1990-11-08 1997-08-13 高砂香料工業株式会社 Process for producing (1'R, 3S) -3- (1'-hydroxyethyl) -azetidin-2-one or a derivative thereof
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
JP3144624B2 (en) * 1995-06-02 2001-03-12 杏林製薬株式会社 N-benzyldioxothiazolidylbenzamide derivative and method for producing the same
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
AU2001292874B2 (en) * 2000-09-27 2006-06-15 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
AU2002231688A1 (en) * 2000-12-21 2002-07-01 Sanofi-Aventis Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
HRP20030498A2 (en) * 2000-12-21 2005-04-30 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
AU2002251978B2 (en) * 2001-02-09 2007-07-19 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
WO2002072104A2 (en) * 2001-03-08 2002-09-19 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOSOGLOU T. ET AL: "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions", ATHEROSCLEROSIS, vol. 2, no. Suppl, 2001, pages 89, XP001132089 *
THOMPSON G. R. ET AL: "Novel lipid regulating drugs", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 9, no. 11, November 2000 (2000-11-01), pages 2619 - 2627, XP008011782 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7417039B2 (en) 2001-01-26 2008-08-26 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7612058B2 (en) 2001-01-26 2009-11-03 Schering Corporation Methods for inhibiting sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7132415B2 (en) 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7560449B2 (en) 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368563B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7378518B2 (en) 2003-03-07 2008-05-27 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7368562B2 (en) 2003-03-07 2008-05-06 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof

Also Published As

Publication number Publication date
EP2039357A2 (en) 2009-03-25
ECSP074704A (en) 2008-01-23
PL369033A1 (en) 2005-04-18
AR066143A2 (en) 2009-07-29
ES2286233T3 (en) 2007-12-01
US20030069221A1 (en) 2003-04-10
EP1385548A2 (en) 2004-02-04
CN1582168A (en) 2005-02-16
WO2002058731A2 (en) 2002-08-01
DK1385548T3 (en) 2007-09-10
AR032643A1 (en) 2003-11-19
PT1385548E (en) 2007-08-24
DE60220269T2 (en) 2008-01-17
EP1385548B1 (en) 2007-05-23
NO20033358D0 (en) 2003-07-25
CA2434436A1 (en) 2002-08-01
SI1385548T1 (en) 2007-10-31
HK1060854A1 (en) 2004-08-27
KR20080077033A (en) 2008-08-20
JP2004517919A (en) 2004-06-17
AU2002241903B2 (en) 2005-11-24
RU2003126186A (en) 2005-03-10
CZ20032031A3 (en) 2003-12-17
IL190173A0 (en) 2008-08-07
EP1541175A2 (en) 2005-06-15
SK9492003A3 (en) 2003-12-02
EP1541175A3 (en) 2006-04-12
ATE362757T1 (en) 2007-06-15
KR20040025889A (en) 2004-03-26
MXPA03006724A (en) 2003-10-24
NZ545332A (en) 2007-09-28
BR0206644A (en) 2004-02-25
NO20033358L (en) 2003-09-12
DE60220269D1 (en) 2007-07-05
HUP0303923A2 (en) 2004-03-01
IL156585A0 (en) 2004-01-04
CY1106791T1 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
WO2002058731A3 (en) Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO2002058734A3 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
EP1785144A3 (en) Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
WO2002058685A3 (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
WO2002058732A3 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
WO2005046797A3 (en) Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
IL175949A0 (en) Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxy steroid dehydrogenase type1 (11-beta-hsd-1) for the treatment of diabetes and obesity
MXPA04002572A (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s).
WO2006024018A3 (en) Compositions for treating nociceptive pain
WO2002058696A3 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
WO2005005453A3 (en) Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
WO2004073623A3 (en) Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
WO2004017948A3 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2004075852A3 (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
EP2266561A3 (en) IKK Inhibitors for the Treatment of Endometriosis
WO2002055530A3 (en) Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
WO2001087343A3 (en) Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor
WO2005096704A3 (en) Cholesterol lowering composition
WO2002062391A3 (en) Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
WO2007115997A3 (en) Combination preparations from modafinil, ritalin and topiramat for use in cocaine dependency and/or for treating impulse control disorders
EP1864680A3 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ECSP034703A (en) COMBINATIONS OF STEROL ABSORPTION INHIBITOR (S) WITH CARDIOVASCULAR AGENT (S) FOR THE TREATMENT OF VASCULAR CONDITIONS
AU2002251865A1 (en) Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UA UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 526527

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 156585

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500566

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2002707500

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002241903

Country of ref document: AU

Ref document number: 2434436

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002559065

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/05692

Country of ref document: ZA

Ref document number: 200305692

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2003-2031

Country of ref document: CZ

Ref document number: 1020037009793

Country of ref document: KR

Ref document number: 9492003

Country of ref document: SK

Ref document number: 1150/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006724

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 028042190

Country of ref document: CN

Ref document number: 03064029

Country of ref document: CO

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-2031

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002707500

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037009793

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2002241903

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12006501541

Country of ref document: PH

WWW Wipo information: withdrawn in national office

Ref document number: 12006501541

Country of ref document: PH

WWG Wipo information: grant in national office

Ref document number: 2002707500

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 190173

Country of ref document: IL